Catalent/CTLT

$58.29

-0.81%
-
1D1W1MYTD1YMAX

About Catalent

Catalent, Inc. is engaged in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. The Company’s Biologics segment provides development and manufacturing of biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for complex oral solids, softgel formulations, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.

Ticker

CTLT

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Alessandro Maselli

Employees

17,800

Headquarters

Somerset, United States

Catalent Metrics

BasicAdvanced
$10.62B
Market cap
-
P/E ratio
-$7.18
EPS
1.21
Beta
-
Dividend rate

What the Analysts think about Catalent

Analyst Ratings

Majority rating from 14 analysts.
Hold

Price Targets

Average projection from 11 analysts.
1.66% downside
High $63.50
Low $42.00
$58.29
Current price
$57.32
Average price target

Catalent Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-20.11% profit margin
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$1.02B
4.28%
Net income
$-206M
-72.86%
Profit margin
-20.11%
-73.98%

Catalent Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 1,055.57%
QuarterlyAnnual
Q3 23
Q4 23
Q1 24
Q2 24
Q3 24
Actual
-$0.09
$0.09
-$0.10
-$0.24
-
Expected
-$0.03
$0.10
-$0.14
-$0.02
$0.20
Surprise
225%
-13.04%
-26.55%
1,055.57%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Catalent stock

Buy or sell Catalent stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing